Results 171 to 180 of about 2,075,366 (204)

Abstract 4344879: Diagnostic Performance of the ATTR-CM Mayo Score in Black and Hispanic individuals: Findings from SCAN-MP

Circulation
Background: The Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score was developed to screen for ATTR-CM and guide referral for 99mTc-pyrophosphate imaging.
N. Barrera, Sergio Teruya, S. Helmke, Rabah Alreshq, D. Fine, Ikram Ullah, F. Raiszadeh, Natalia Ionescu, Cesia Gallegos, Frederick L. Ruberg, Edward Miller, Mathew S. Maurer   +11 more
semanticscholar   +1 more source

Abstract 4369739: Refining Prediction of Cerebrovascular Events in ATTR-CM with Sinus Rhythm to Guide Preventive Anticoagulation

Circulation
Background: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) face a significant risk of cerebrovascular events, even when in sinus rhythm (SR). However, no validated tool exists to identify those at highest risk.
A. Porcari, B. Dal Passo, L. Venneri, Francesco Bandera, Y. Razvi, A. Sheikh, J. Mansell, E. Zaro, Gaia Giampieri, Scott D. Solomon, A. Martinez-Naharro, P. Hawkins, Julian D. Gillmore, Marianna Fontana   +13 more
semanticscholar   +1 more source

Assessing functional capacity in patients with ATTR-CM: the role of CPET and 6MWT

European Heart Journal
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiac disorder leading to heart failure and reduced functional capacity.
A. Sheikh, A. Ioannou, A. Porcari, R. Patel, Y. Razvi, J. Mansell, F. Bandera, L. Venneri, A. Martinez-Naharro, C. Whelan, D. Knight, H. Lachmann, P. Hawkins, J. Gillmore, M. Fontana   +14 more
semanticscholar   +1 more source

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) cardiogenomics: a tertiary centre experience

European Heart Journal
ATTR-CM results from the accumulation of wild-type (wtATTR-CM) or mutated/variant (hATTR-CM) transthyretin in the heart. The differentiation between these two subtypes often supports the use of specific treatments and family counselling/screening ...
R. Amador, R. Carvalho, O. Moldovan, T. Laranjeira, S. Maltes, C. Aguiar, B. Rocha   +6 more
semanticscholar   +1 more source

ECHOCARDIOGRAPHIC AND DEMOGRAPHIC CHARACTERISTICS OF A POPULATION WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CM)

Journal of the American College of Cardiology
Melanie Sun, Mosi Kadin Bennett, Peter Eckman, Sarah Schwager, Evan Walser-Kuntz, Siu-Hin Wan   +5 more
openaire   +2 more sources

Misdiagnosis rates in ATTR-CM patients and associated symptoms

European Heart Journal
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, progressive cardiac condition caused by the accumulation of misfolded transthyretin protein in the heart.
P. Collins, N. Melinis, W. Chung, F. Hefni, R. Hegde, O. Ozbey, B. Cheng, T. Y. Loo   +7 more
semanticscholar   +1 more source

Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline

European Heart Journal
The National Amyloidosis Centre (NAC) staging system is used to stratify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) into prognostic categories.[1] This post hoc analysis evaluated all-cause and cardiovascular (CV)-related ...
T. Damy, F. Angeli, R. Wang, M. Maurer, M. Fontana   +4 more
semanticscholar   +1 more source

Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension

European Heart Journal
Patients with ATTR-CM can have lower circulating TTR levels, which is associated with worsening of cardiac function and increased risk of cardiovascular mortality.[1] Acoramidis has been shown to reduce cardiovascular mortality and hospitalization,
M. Maurer, F. Cappelli, M. Fontana, P. García-Pavía, M. Grogan, M. Hanna, D. Judge, A. Masri, J. Du, S. Siddhanti, J. Tamby, A. Ji, U. Sinha, J. Fox, J. Gilmore   +14 more
semanticscholar   +1 more source

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM

European Heart Journal
Abstract Background The pathophysiological hallmark of transthyretin amyloid cardiomyopathy (ATTR-CM) is the deposition of amyloid within the myocardium. However, the association between myocardial amyloid load and quantitative cardiac 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD ...
R Rettl, R Calabretta, F Duca, C Kronberger, C Binder, R Willixhofer, C Dona, D Beitzke, C Loewe, C Nitsche, C Hengstenberg, R Badr Eslam, J Bergler-Klein, M Hacker, A Kammerlander   +14 more
openaire   +1 more source

PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN UNDIFFERENTIATED HFPEF

Journal of the American College of Cardiology, 2023
Liam Healy, Niall Mahon
openaire   +1 more source